AbbVie (NYSE: ABBV) reported Q2 EPS of $3.65, $0.06 worse than the analyst estimate of $3.71. Revenue for the quarter came in at $16.99 billion versus the consensus estimate of $16.77 billion.

GUIDANCE:

AbbVie sees FY2026 EPS of $13.87-$14.07, versus the consensus of $14.12.

For earnings history and earnings-related data on AbbVie (ABBV) click here.